MoonLake Immunotherapeutics
MoonLake Immunotherapeutics, a clinical-stage biopharmaceutical company, engages in developing therapies. It is developing Sonelokimab, a novel investigational Nanobody therapy for the treatment of inflammation. The company is involved in conducting Phas…
Biotechnology
CH, Zug [HQ]
FA
Fundamental Analysis · Most Recent Quarter
A dedicated fundamental analysis might help you to get a quick overview
of the
financial stability. It is important to understand the
FA Algorithm
and the criterias before valuing it as a top-tier resource.
Fundamentals
Valuation
| Metric | Q4 | Q1 | Δ in % | |
|---|---|---|---|---|
| EV/EBITDA | 38.02 | -130.79 | -211.02 | |
| Graham Fair Price | 35.70 | 6.52 | 4.81 | |
| PEG | -81.70 | -0.67 | 3.65 | |
| Price/Book | -23.14 | 5.61 | 7.30 | |
| Price/Cash Flow | 29.91 | -200.80 | -286.50 | |
| Prices/Earnings | 54.24 | -55.66 | -121.63 | |
| Price/Sales | inf | 0.00 | 183313.52 | |
| Price/FCF | 29.91 | -200.80 | -286.50 | |
| Naive Interpretation | member | |||
01 - Valuation ·
Weak
Fundamentals
Profitability
| Metric | Q4 | Q1 | Δ in % | |
|---|---|---|---|---|
| Gross Profit Margin | inf | 0.00 | 0.83 | |
| Operating Margin | inf | 0.00 | -761.42 | |
| ROA | -71.61 | -0.02 | -0.01 | |
| ROE | -0.02 | -0.03 | -67.97 | |
| ROIC | -0.03 | -0.04 | -20.50 | |
| Naive Interpretation | member | |||
02 - Profitability ·
Not Interpreted
Fundamentals
Financial Growth
| Metric | Q4 | Q1 | Δ in % | |
|---|---|---|---|---|
| Debt QOQ | < 0.005 | 20.83 | -99.95 | |
| Dividends QOQ | 0.00 | 0.00 | 0.00 | |
| EBIT QOQ | -0.16 | -0.32 | -101.61 | |
| EPS QOQ | 0.33 | -0.83 | 150.00 | |
| FCF QOQ | -0.37 | -0.20 | 45.12 | |
| Revenue QOQ | 0.00 | -1.00 | -100.00 | |
| Naive Interpretation | member | |||
03 - Financial Growth ·
Balanced
Fundamentals
Leverage & Liquidity
| Metric | Q4 | Q1 | Δ in % | |
|---|---|---|---|---|
| Assets Turnover | n.A. | n.A. | n.A. | |
| Days Inventory Outstanding (DIO) | 0.00 | 0.00 | 0.00 | |
| Days Sales Outstanding (DSO) | 4819.01 | 0.00 | inf | |
| Inventory Turnover | 0.00 | 0.00 | 0.00 | |
| Debt/Capitalization | < 0.005 | < 0.005 | -9.46 | |
| Quick Ratio | 51.38 | 61.56 | 19.81 | |
| Naive Interpretation | member | |||
04 - Leverage & Liquidity ·
Weak
Fundamentals
Per Share Metrics
| Metric | Q4 | Q1 | Δ in % | |
|---|---|---|---|---|
| Book Value | 8.27 | 8.66 | 4.70 | |
| Cash | 8.53 | 8.73 | 2.40 | |
| Capex | < 0.005 | < 0.005 | 28.83 | |
| Free Cash Flow | -0.21 | -0.24 | -14.82 | |
| Revenue | < 0.005 | 0.00 | inf | |
| Naive Interpretation | member | |||
05 - Per Share Metrics ·
Positive
Fundamentals
Financial Health
06 - Financial Health ·
Bad